Inhibition of human perforin dysfunction in autoimmunity

We aim to develop inhibitory antibodies that can inhibit secreted perforin function using the Beacon Optofluidic System and Monash Antibody Technology Facility (MATF) service. The service provides a more competitive antibody screening platform than the traditional platforms in terms of speed (reducing the time from months to days) and sensitivity (harvesting the rare clones). If successful, the proposed project will further develop the first-in-class immunotherapeutic of broad utility in combating many difficult-to-treat auto-immune conditions.